Tag:
solanezumab
Latest Headlines
Latest Headlines
UPDATED: Baxter adds Gammagard to growing roster of PhIII Alzheimer's failures
The long and frustrating search for something--anything--that can treat Alzheimer's or blunt its symptoms ran into yet another Phase III roadblock this morning as Baxter International reported that its Phase III study of the immune-bolstering treatment Gammagard ended in failure.
Merck CEO pledges to persist with 'good' cholesterol drug program
Even as failures in the field pile up, Merck CEO Kenneth Frazier is pushing ahead with a massive development program for a drug to boost HDL or "good" cholesterol.
Alzheimer's investigators pick Lilly's sola in big prevention study
Eli Lilly's ($LLY) solanezumab has secured an endorsement from Alzheimer's researchers, who will study the experimental drug as a preventive therapy against the memory-robbing disease in patients before symptoms emerge.
UPDATED: Eli Lilly ditches FDA filing for Alzheimer's hope solanezumab
After meetings with top regulators, Eli Lilly has opted to wait on filing for U.S. and European approvals of its closely watched Alzheimer's candidate solanezumab. Instead, the Indianapolis-based drug giant will embark on a new Phase III study to further investigate whether the antibody therapy slows cognitive declines in patients with the memory-robbing disease.
Tau theory comes center stage in Alzheimer's R&D as amyloid advocates regroup
Alzheimer's research has been dominated for years by the amyloid beta hypothesis: Toxic loads of the protein build up in the brain, blighting its ability to retain memories. Cut amyloid levels, say advocates, and you can delay or prevent the disease.
Alzheimer's investigators see fresh sign of solanezumab success in Eli Lilly study
In the two pivotal Phase III studies of the drug, investigators determined that there was a noticeable effect on the level of beta amyloid found in patients' blood, suggesting that solanezumab had reduced levels of the toxic protein in the brain.
Pioneering study will test if trio of Roche, Lilly drugs can prevent Alzheimer's
Washington University School of Medicine in St. Louis has pieced together a pioneering new study that will help put a new theory on preventing Alzheimer's to a definitive test. And the outcome could help pave the way for a megablockbuster approach to treating a disease that afflicts millions.
UPDATED: Eli Lilly surges on conflicting data for Alzheimer's drug solanezumab
Shares of Eli Lilly surged today after investigators spelled out the encouraging solanezumab data they plucked out of a secondary analysis of a group of patients with a mild form of the memory-wasting disease.
The Top Phase III Disasters of 2012
Drug development is a tough business. Sometimes, just when you think you're getting to the pot at the end of the rainbow, you find the trap door one step away. It's not supposed to work that...
The top Phase III disasters in 2012
2012 has seen some of the biggest failures in the history of drug R&D.
Click here to see my top 5 flops of the year >>
